A key heuristic for deciding between second-line endocrine therapy versus chemotherapy/ADC is the duration of benefit from the first-line CDK4/6 inhibitor. Patients who progress after a long duration (e.g., >18 months) are likely still endocrine-sensitive and should receive further endocrine-based therapy. Rapid progression (e.g., <6 months) suggests endocrine resistance, warranting a potential switch in modality.

The traditional definition of platinum-resistant ovarian cancer based on a six-month recurrence interval is becoming less rigid. Clinicians recognize this timeframe can be an arbitrary surrogate for tumor biology, influenced by imaging schedules. The paradigm is shifting, especially post-PARP inhibitor therapy, where the value of re-challenging with platinum is being reconsidered despite shorter intervals.

The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.

Patients in recent international adjuvant trials like MONARCH-E, NATALI, and LADERA have a significantly higher baseline risk of recurrence compared to those in US-centric studies like TaylorX. Three-year event rates are two to four times higher, which is critical context for applying these findings and assessing the cost-benefit of new, toxic therapies for average-risk patients.

When a gynecologic cancer recurs, the decision to perform a new biopsy for HER2 testing is often time-dependent. Clinicians may use a ~12-month interval as a practical threshold. A longer time since initial diagnosis increases the likelihood of tumor evolution, making a new biopsy necessary to accurately guide therapy for the current tumor rather than relying on historical data.

A patient's time to progression on first-line CDK4/6 inhibitor therapy acts as an informal biomarker. A shorter duration, such as 14 months, is viewed by experts as "not so great" and indicates a degree of underlying endocrine resistance that influences subsequent treatment strategies.

Patients who recur shortly after adjuvant CDK inhibitor therapy have aggressive tumors and a poor prognosis. Clinical series show that when these patients are treated with a CDK inhibitor in the first-line metastatic setting, the median progression-free survival is only around three months, indicating profound pre-existing resistance.

Despite acknowledging that a one-size-fits-all treatment duration is suboptimal, the expert consensus is to follow the study protocol. This conservative, evidence-based approach prevails due to the absence of validated biomarkers, like ctDNA, to safely guide treatment de-escalation for individual patients.

Clinical trials use arbitrary, time-based definitions (e.g., relapse within 2 years) for endocrine resistance. This isn't a perfect biological classification but a practical necessity to create homogeneous patient groups for testing, which may not fully reflect the diverse patient population in clinical practice.